Milestone Tranches in Dutch BV Financings

Translating US VC terms into Dutch mechanics

Milestone tranches in Dutch BV financings are investment structures where funding is released in stages, usually after the company reaches agreed operational, technical, regulatory or commercial milestones. They are common in US venture financings, especially where valuation remains difficult, investor risk is high or a company’s next value inflection point is clearly identifiable.

This article forms part of the US VC Terms & Dutch BV Structures Insights series, which focuses on the Dutch implementation of US-style venture capital terms in Dutch BV financings.

Milestone tranches can be useful. They allow investors to commit capital while controlling downside risk. They allow founders to avoid pricing the entire round too defensively. But in a Dutch BV structure, tranche-based financing should not be treated as a simple funding schedule. The real issues are usually found in the mechanics: share issuance, conversion, shareholder approvals, pre-emption waivers, investor consent rights and the consequences of missing a milestone.

Why US-style tranches need Dutch implementation

US venture documents often assume a familiar corporate framework for issuing preferred stock, adjusting investor rights and funding later tranches. A Dutch BV works differently.

A Dutch financing involving shares will usually require careful alignment between the investment agreement, the shareholders’ agreement and the articles of association. If new shares are issued upon each tranche, the notarial and corporate approval mechanics must be mapped from the start. If a convertible instrument is used, the future conversion mechanics should be clear before the first tranche is funded.

This is where imported US documents can create friction. The commercial deal may say that a second tranche is released upon FDA approval, product launch, revenue targets or investor consent. But the Dutch documents must explain what legally happens when the milestone is achieved, who determines achievement, what shares are issued, what approvals are required and what happens if the milestone is disputed.

The milestone definition is a negotiation point

In practice, milestone drafting is often more important than the amount of the tranche itself.

Founders usually want milestones that are objective, achievable and not fully dependent on investor discretion. Investors want milestones that genuinely reduce risk and are not satisfied by superficial progress. The tension is obvious. A broad milestone may give the company funding certainty, but weak protection for the investor. A narrow milestone may protect the investor, but create operational uncertainty for the company.

In Dutch BV financings, this negotiation should also be linked to governance. If investors have veto rights over budgets, hiring, product strategy or regulatory decisions, they may indirectly influence whether a milestone is reached. That should be considered when drafting both the milestone language and the reserved matters.

Missing a milestone should not create uncertainty

A tranche structure should clearly state what happens if the milestone is not achieved. This is often where documentation becomes too vague.

Does the investor lose the obligation to fund? Does the company have a cure period? Can the parties waive the milestone? Is the next tranche cancelled, delayed or renegotiated? Does the valuation change? Are existing rights affected? Can the company raise money from others?

These questions matter because failure to reach a milestone can occur precisely when the company is under pressure. If the documents are unclear, the missed milestone can turn into a shareholder dispute, a down-round negotiation or a blocking position over new financing.

For Dutch founders and boards, this is also a governance issue. The company may need to continue operating even if the next tranche is not funded. The board should therefore understand whether the tranche structure creates a genuine financing commitment or only a conditional option for investors.

Tranches can affect dilution and control

Milestone tranches often affect dilution mechanics. If later tranches are funded at the same valuation, founders may accept more dilution once risk has decreased. If the later tranche is priced differently, the documents need to explain how the new valuation interacts with existing anti-dilution protection, option pools and investor participation rights.

In a Dutch BV, these economics must be implemented through the actual issue of shares or conversion of instruments. That means the articles of association and shareholders’ agreement should be reviewed before the structure is finalised.

Control is equally important. Investors may require stronger consent rights between tranches, especially if further funding depends on performance. Founders should be careful that these rights do not make the business too difficult to operate or raise replacement capital if the milestone is missed.

Practical conclusion

Milestone tranches can be effective in Dutch BV financings, especially where US investors want to manage risk while supporting a company through a defined value inflection point. But they require more than copying US VC drafting.

The key issue is whether the tranche structure works inside the Dutch BV. That requires clear milestone definitions, workable funding obligations, aligned shareholder approvals, proper share issuance or conversion mechanics and a governance structure that does not create unnecessary deadlock.

For US investors and cross-border counsel, the commercial concept will be familiar. The Dutch implementation should not be assumed.

FAQ

What is a milestone tranche in a VC financing?

A milestone tranche is a funding structure where investment is provided in stages, usually after the company achieves agreed milestones such as regulatory approval, product development, revenue targets or other value inflection points.

Can milestone tranches be used in Dutch BV financings?

Yes. They can be used, but the structure must be adapted to Dutch BV mechanics, including share issuance, conversion, shareholder approvals, pre-emption waivers and notarial implementation where relevant.

What is the main risk for founders?

The main risk is that the company depends on later funding that may not be released if the milestone is missed or disputed. This can create financing pressure and give investors significant leverage.

What is the main risk for investors?

The main risk is that the milestone is drafted too broadly or that the Dutch implementation does not properly connect the funding obligation to share issuance, conversion rights and governance protections.

Dutch implementation of US-style milestone financings

Milestone tranches can bridge valuation uncertainty and investor risk, but only if the structure is properly translated into Dutch BV documentation and governance mechanics.

Dirk de Waard, partner at Venture M&A Lawyers, advises founders, investors, scale-ups and cross-border deal counsel on Dutch VC transactions, Dutch BV governance and US-style investor rights in Dutch financings. Having studied at Cornell Law School, Dirk is familiar with the way US investors and advisors approach venture capital terms, while focusing on their practical implementation in Dutch BV structures.

For support with Dutch VC documentation, milestone-based financings or Dutch BV investment mechanics, contact Dirk de Waard.